In the US, Sargramostim (sargramostim systemic) is a member of the drug class colony stimulating factors and is used to treat Aplastic Anemia, Bone Marrow Transplantation, Bone Marrow Transplantation - Failure or Engraftment Delay, Bone Marrow Transplantation - Myeloid Reconstruction and Neutropenia Associated with Chemotherapy.
ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
Colony stimulating factor, granulocyte-macrophage, GM-CSF
23-L-Leucinecolony-stimulating factor 2 (human clone pHG25 protein moiety)
- Sargramostimum (Latin)
- Sargramostim (German)
- Sargramostim (French)
- Sargramostim (Spanish)
- Sargramostim (OS: BAN, USAN, DCF)
- Sargramostim (Genetical Recombination) (OS: JAN)
- BI 61012 (IS)
- BL 400 (IS)
- rGM-CSF (IS)
- rHu GM-CSF (IS)
- Sargramostim (PH: USP 37)
Yousuf Mahmood Husain, Bahrain
|BAN||British Approved Name|
|DCF||Dénomination Commune Française|
|JAN||Japanese Accepted Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
Click for further information on drug naming conventions and International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.